Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Protagonist Therapeutics (PTGX)

Protagonist Therapeutics: Suneel Gupta moves to Executive Vice President, Clinical Development

Neutral Impact 2 of 5 leadership Written later

Effective January 1, 2025, Suneel Gupta, Ph.D., transitioned from Chief Development Officer to Executive Vice President, Clinical Development at Protagonist Therapeutics. The filing is a role change for a senior executive, and it does not disclose financial results, compensation terms, or a new hire.

Key points

  • Effective date of the change: January 1, 2025
  • Suneel Gupta, Ph.D., moved from Chief Development Officer to Executive Vice President, Clinical Development
  • The filing was signed by Chief Financial Officer Asif Ali on January 6, 2025

The filing

CompanyProtagonist Therapeutics (PTGX)
Form8-K, current report
Filed with the SECJan 6, 2025, 4:05 PM ET
Accession number0001104659-25-001304

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.